Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the <scp>FDA</scp> Adverse Event Reporting System ( <scp>FAERS</scp> ) database
Gepants display distinct AE profiles, with oral agents linked to gastrointestinal and neurological effects and intranasal zavegepant associated with respiratory irritation. Continued post-marketing surveillance is essential to inform personalized migraine management and guide future CGRP-targeted drug development.
Authors
- Yan Li
- Hui Chen
Institutions
- Fourth People’s Hospital of Jinan (CN)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1111/head.70049
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00